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 CURRENTOPINION Update on adjuvant melanoma therapy
Florentia Dimitrioua, Ralph Peter Brauna,b, and Joanna Manganaa
Purpose of review
We review the results from relevant clinical trials and discuss current strategies in the melanoma adjuvant
setting.
Recent findings
The favorable therapeutic efficacy and the significant less toxicity of nivolumab compared with ipilimumab,
fully substitutes today‘s approval of ipilimumab, regardless mutation status, whereas in BRAF-mutated
patients, dabrafenib and trametinib seem to confirm their high efficacy also in adjuvant setting. The use of
interferon is restricted to patients with ulcerated melanoma and countries with no access to the new drugs.
Summary
Systemic adjuvant treatment after complete disease resection in high-risk melanoma patients aims to
increase relapse-free survival (RFS) and overall survival (OS). According to the eighth edition of melanoma
classification of American Joint Committee on Cancer (AJCC), the prognosis in stage III patients is
heterogeneous and depends not only on N (nodal) but also on T (tumor thickness) category criteria. Recent
data from randomized, phase-3 clinical trials analyzing the use of adjuvant anti-programmed death-1 and
targeted therapies ultimately affect the standard of care and change the landscape of the adjuvant
treatment.
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INTRODUCTION
Checkpoint inhibitors as well as inhibitors of the
mitogen-activated protein kinase pathway (MAPK)
revolutionized the treatment era of advanced mela-
nomapatients leading to their approval formetastatic
disease [1–8,9
&&
,10–16,17
&&
,18,19
&
,20]. Recently,
spectacular outcomes were equivalently demon-
strated in the adjuvant setting of patients with high
risk for recurrence; however, choosing the right treat-
ment at the right time remains an important clinical
challenge [21,22
&&
,23
&&
,24]. Taking into account the
high heterogeneity in stage III population and based
on the American Joint Committee on Cancer (AJCC)
staging system, the likelihood of recurrence or sys-
temic disease correlates closely with tumor thickness
and ulceration, microscopic versus macroscopic dis-
ease, the number of positive nodes as well as with
presence of (micro)satellites or intransit metastasis
[25,26]. Furthermore, the outcome of the sentinel
lymph node biopsy (SLNB) is used for identification
of high-risk groups, and decisions on frequency of
follow-up, adjuvant therapy and enrollment into
clinical trials [27–29].
This review will focus on the recent advances
and the impact of immunotherapies and MAPK
pathway-targeted therapies on clinical outcomes
of high-risk melanoma patients. It will also examine
the rationale behind current treatment choices in
the real-life adjuvant setting.
RADIOTHERAPY
Radiotherapy provides an important variant in the
treatment of patients with recurrent, in-transit or
nodal metastatic melanoma requiring local control
[30]. In the ANZMTG 01.02/TROC 02.01 phase 3,
randomized controlled trial, 250 patients were
enrolled to receive adjuvant radiotherapy of 48Gy
in 20 fractions or observation (OBS) [31]. The use of
adjuvant radiotherapy after complete surgical resec-
tion significantly reduced the melanoma relapse in
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the adjuvant radiotherapy group compared with
OBS, but no differences regarding relapse-free sur-
vival (RFS) and overall survival (OS) were noted [31].
Long-term follow-up data support the primary find-
ings. After a median follow-up of 73 months, 21%
relapses occurred in the adjuvant radiotherapy
group compared with 36% in the OBS group [hazard
ratio 0.52, 95% confidence interval (CI) 0.31–0.88,
P¼0.023] [32]. However, no significant difference
regarding OS (hazard ratio 1.27, 95% CI 0.89–1.79,
P¼0.21) and RFS (hazard ratio 0.89, 95% CI 0.65–
1.22, P¼0.51) was noted.
IMMUNOTHERAPY
Melanoma has been long considered an immuno-
genic cancer inducing significant antitumor
responses and in some cases, spontaneous regression
after immune-stimulating agent treatment [33–35].
As a result, multiple efforts in cytokine therapy,
tumor vaccines, oncolytic viruses, adoptive immu-
notherapy and immune check point inhibition have
been evaluated [33]. Some of these agents showed
impressive activity not only inmetastatic but also in
the adjuvant setting and will be discussed here in
further detail.
Interferons
Over the last 30 years, interferon (IFN) has been
extensively investigated in patients with high-risk
melanoma [36–44] (Table 1). Despite showing a
rather modest activity – particularly whenever bal-
anced against toxicity – it was the first agent world-
wide approved in this setting. However, and partly
because of substantial toxicity and treatment
costs, there is a significant variation in different
geographic locations regarding its use. High-dose
IFN (HDI) for 12 months was until recently the
KEY POINTS
 The disease prognosis in stage III patients is
heterogeneous and depends not only on N but also on
T category criteria, according to the eighth edition of
melanoma classification of American Joint Committee
on Cancer (AJCC).
 According to the recent clinical trials outcomes, current
adjuvant treatment options are nivolumab for all
patients regardless mutation status and dabrafenib/
trametinib for BRAF-mutated patients.
 The use of interferon is restricted to patients with
ulcerated melanoma in countries with no access to the
new drugs.
 Neoadjuvant therapy, upcoming adjuvant treatment
combinations, for example, nivolumab with ipilimumab
and identification of new biomarkers are expected to
maximize the antitumor response.
Table 1. Adjuvant trials determining adjuvant treatment in melanoma
Study Stage at study entry Treatment arms (N)
Median follow-
up (years) RFS OS Reference
ECOG E1684 II and III (T4N0M0/
TanyNþM0)
High-dose IFNa2a (HDI)
versus observation (287)
6.9 0.61 0.67 Kirkwood
et al. [45]
12.6 0.72 0.82
ECOG E1690 II and III (T4N0M0/
TanyNþM0)
HDI or LDI versus observation
(642)
4.3 0.78 1.0 Kirkwood
et al. [46]
6.6 0.81 1.0
ECOG E1694 II and III (T4N0M0/
TanyNþM0)
HDI versus GMK vaccine for
96 weeks (880)
1.3 0.67 0.72 Kirkwood
et al. [47]
2.1 0.75 0.76
EORTC 18991 III [Tany, N1(occult)/
N2 (bulky), M0]
Pegylated IFNa2b versus
observation (1256)
3.8 0.82 0.98 Eggermont
et al. [37]
7.6 0.87 0.96
EORTC 18071 IIIA (N2a)/IIIB/IIIC
(except in transit)
Ipilimumab 10mg/kg versus
placebo (951)
5.3 0.76 0.72 Eggermont
et al. [24]
COMBI-AD IIIA (>1mm)/IIIB/IIIC Dabrafenib 150mg b.i.d. with
trametinib 2mg q.d. versus
placebo (870)
2.8 0.47 0.57 Long et al.
[23&&]
Checkmate-238 IIIB/IIIC/IV Nivolumab 3mg/kg versus
ipilimumab 10mg/kg (906)
1.5 0.65 ? Weber et al.
[22&&]
OS, overall survival; RFS, relapse-free survival.
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standard of care in the United States and Australia,
whereas intermediate and low doses are used in
Europe and pegylated IFN is only approved in
Switzerland for patients with micrometastasis and
ulcerated primary tumors.
The E1684 clinical trial was the first trial dem-
onstrating an improvement both in OS and RFS after
a median follow-up time of 6.9 years. It investigated
an induction phase of HDI intravenously adminis-
tered at 20MU/m2 for five consecutive weeks fol-
lowed by subcutaneous administration of 10MU/m2
of IFN three times a week for 48 weeks versus pla-
cebo. 5-year RFS was 37% (95% CI 30–46%) com-
pared with 26% (95% CI 19–34%), and 5-year OS
was 46% (95% CI 39–55%) versus 37% (95% CI 30–
46%) in favor of HDI [45]. HDI for 1 year and low-
dose IFN for a treatment period of 2 years were
compared with postoperative OBS in the E1690 trial
[46]. HDI significantly improved RFS (P¼0.03) com-
pared with OBS after a median follow-up of 4.3
years, but no differences were seen in OS. E1694
trial followed and tested HDI for 1 year versus the
ganglioside vaccine GMK (Progenics pharmaceuti-
cals) for 96 weeks [47]. Herein, OS and RFS were
significantly improved in favor of HDI (hazard ratio
0.72 and 0.67, respectively). Subsequently, a num-
ber of trials trying to identify the optimal dose,
schedule and duration of adjuvant IFN have fol-
lowed [38,41,48–52]. In a pooled meta-analysis of
nearly 2000 patients including E1684, E1690 and
E1694 trials, HDI maintained substantial RFS but
not OS benefit (P¼0.006) [39]. Other meta-analyses
demonstrated a modest impact in OS (approxi-
mately 3%, 95% CI 1–5%) with ulceration being
the most predictive factor for response to IFN
[37,40,42,48,53–55].
CTLA-4 inhibition
Ipilimumab, a fully human monoclonal antibody
that blocks CTLA-4, was approved by the Federal
Drug Administration (FDA) for treatment of patients
with advanced melanoma in 2011 [11]. The efficacy
of ipilimumab in the adjuvant setting has been
evaluated in two randomized phase III clinical trials
either compared with placebo (EORTC 18071) [21]
or HDI (ECOG 1609, NTC01274338).
The EORTC 18071 clinical trial enrolled 951
melanoma patients with stage IIIA (N2a), IIIB and
IIIC disease after complete resection and high risk of
recurrence [21]. Patients were 1 : 1 randomly
assigned to receive ipilimumab at a dose of 10mg/
kg or placebo every 3 weeks for four doses, following
every 3 months for up to 3 years. The study met its
primary endpoint of RFS in 2.7 years. Ipilimumab
was shown to significantly improve RFS at 26.1
months (95% CI 19.3–39.3) compared with 17.1
months (95% CI 13.4–21.6) in the placebo group
(hazard ratio 0.75, 95% CI 0.64–0.90, P¼0.0013)
[21]. Recent data of 5.3 years’ median follow-up
confirm the RFS and OS benefit (RFS 40.8 versus
30.3%, hazard ratio 0.76, 95%CI 0.64–0.89, OS 65.4
versus 54.4%, hazard ratio 0.72, 95% CI 0.58–0.88)
[24] (Table 1). Benefit was consistent in all sub-
groups, though patients with ulcerated primary
lesions seem to benefit the most.
As current dose of ipilimumab 10mg/kg in the
adjuvant setting is significantly higher than the
dose approved for metastatic melanoma (3mg/kg),
questions have been raised regarding the dose rela-
tion to higher toxicity [56]. The ECOG-E1609 clini-
cal trial compares ipilimumab 10 or 3mg/kg versus
high-dose recombinant IFNa in resected stages IIIB
and IIIC (including in-transit metastases) and stage
IV melanoma with primary endpoints, the OS and
progression-free survival (PFS). An unplanned RFS
analysis was recently presented, showing no sub-
stantial difference in PFS for patients treated with
3mg/kg compared with 10mg/kg [57]. Updated
results of this trial are expected in May 2018.
PD1 inhibition
Anti-programmed death-1 (anti-PD1) blockade has
demonstrated significant benefits in RFS and OS in
metastatic melanoma with superior efficacy to ipi-
limumab [8,16,19
&
]. These encouraging data along
with a favorable toxicity profile prompted their
application in the adjuvant setting.
The phase 3 clinical trial comparing ipilimumab
10mg/kg to nivolumab 3mg/kg in fully resected
stage IIIB/IIIC–IV melanoma patients reformed the
adjuvant treatment era (Checkmate-238) [22
&&
]. Nine
hundred and six patients were 1 : 1 randomized to
nivolumab 3mg/kg every 2 weeks versus ipilimumab
10mg/kg every 3 weeks for 4 doses and then every
12 weeks for 1 year till disease recurrence or unac-
ceptable toxicity. After 18monthsof follow-up, nivo-
lumab showeda significant superiority over adjuvant
ipilimumab treatment, with RFS of 70.5% (95% CI
66.1–75.4) versus 60.8% (95% CI 56.0–65.2), hazard
ratio 0.65; P<0.001 [22
&&
]. Adjuvant treatment with
nivolumab seems to have higher benefit in patients
with stage IIIB/IIIC and PD-L1 expression more than
5%, regardless of BRAF status.
Other ongoing clinical trials investigating the
application of anti-PD1 agents in the adjuvant set-
ting are the EORTC 1325 (KEYNOTE-054) compar-
ing pembrolizumab 200mg flat dose versus placebo
(NCT02362594) and the SWOG S1404 protocol
comparing pembrolizumab 200mg flat dose to
HDI [58].
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As combination of CTLA-4 with PD-1 blockade
has been proved to augment the immune response
compared with each agent alone in metastatic mel-
anoma [17
&&
], the Checkmate-915 clinical trial is
currently underway, comparing adjuvant nivolu-
mab combined with ipilimumab versus nivolumab
monotherapy (NCT03068455). This phase-3 study
enrolls patients after complete resection of stage
IIIB/IIIC/IIID or stage IV melanoma, according to
the eighth AJCC edition.
TARGETED THERAPY
In addition to immunotherapy, inhibition of the
MAPK pathway resulted in outstanding activity in
the adjuvant setting as recently presented in the
European Association of Medical Oncology Meeting
(ESMO), this year in Madrid. The Combi-AD ran-
domized double-blind phase III clinical trial
enrolled 870 patients with completed resected stage
III melanoma harboring the BRAF V600E or V600K
mutation to receive either dabrafenib 150mg twice
daily with trametinib at a dose of 2mg once daily or
two matched placebo. Patients were treated for a
maximum of 1 year in the absence of disease pro-
gression or until unacceptable toxicity or study
withdrawal. Among the study population, 18%
(154 patients) had a stage IIIA disease with a micro-
metastasis in SLNB of more than 1mm. At a median
of 2.8 years follow-up, investigation-assessed RFS
was significantly longer in the combination group
resulting in a 53% lower risk for death or relapse
(hazard ratio 0.47; 95% CI 0.39–0.58; P<0.0001).
Estimated rates for RFS at the first, second and third
year were 88, 67 and 58% for the combination group
in comparison with 56, 44 and 39% for the placebo
group, respectively. Combination treatment
resulted in higher rates of OS and distant-metasta-
sis-free survival (DMFS) with a 3-year OS of 86% in
the combination group versus 77% in the placebo
group and a 3-year DMFS of 71 versus 57%, respec-
tively (Table 1). Clinical benefit was consistent
across all subgroups of patients regardless of ulcera-
tion of primary tumor or lymph-node involvement.
The randomized BRIM8 trial of adjuvant vemur-
afenib versus placebo, however, in patients with
resected BRAF-mutant melanoma and high risk of
recurrence did not manage to improve the primary
endpoint of RFS but seems to be effective with
manageable safety profile in patients with stage
IIC–IIIB melanoma [59].
TOXICITY
The toxicity profile in the adjuvant setting is con-
firming the existing experience in advanced
melanoma. Adverse events occur less frequent with
anti-PD1 antibodies than with ipilimumab with a
comparable toxicity profile, including diarrhea,
colitis, endocrinologic adverse events (hypophysi-
tis, hyperthyroidism and hypothyroidism, adrenal
dysfunction), vitiligo, pruritus, rash and fatigue
[60,61]. Patients enrolled in the EORTC 18071 trial
developed a high rate of grade 3–5 immune-related
adverse events (irAEs; 43 compared with 2% in
placebo group), including five treatment-related
deaths (colitis, n¼3; myocarditis, n¼1; multiorgan
failure with Guillan–Barre syndrome, n¼1) [21].
Comparing the safety profile of the Checkmate-
238 trial, nivolumab showed significantly less tox-
icity. Grade 3–4 adverse events occurred in 14.4% of
the patients in the nivolumab group and in 45.9% in
the ipilimumab group and led to discontinuation in
3.5 and 30%, respectively [22
&&
]. These irAEs are,
however, manageable through early application of
high-dose corticosteroids or other immunemodula-
tory agents.
Albeit, immunotherapy and targeted therapy
have different toxicity profiles. Taking a closer look
into the Combi-AD trial, the most common adverse
events appear to be pyrexia, fatigue and nausea,
whereas grade 3–4 toxicities occurred in 41% in
the combination group versus 14% in the placebo
group [23
&&
]. The number of treatment discontinua-
tions seems to be higher compared with stage IV
melanoma (26 versus 16%, respectively, though no
new adverse events were observed.
High-dose interferon-a2b is associated with
high toxicity, such as chronic fatigue (96%), mye-
losuppression (92%), elevated liver enzyme levels
[63% increased aspartate aminotransferase (AST)]
and neurologic symptoms (40%), which affect the
majority of patients and can lead to premature
treatment discontinuation [62].
INTEGRATING CURRENT ADJUVANT
TREATMENT INTO CLINICAL PRACTICE
Putting this data together, there is yet no consen-
sus available for treatment selection in melanoma
patients with high risk for recurrence. As neither
nivolumab nor dabrafenib and trametinib combi-
nation therapy have been so far approved by the
regulatory authorities for this indication, the sug-
gestions that follows are hinged on the results of
the available studies. However, and considering
that the surgical procedures and the staging sys-
tem have changed since the initiation of these
trials, there is a certain gap of knowledge affecting
the adjuvant field. The recommendations that
follows have been adapted to the new AJCC,
eighth edition.
Melanoma and other skin neoplasms
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Taking into account, the modest impact in OS
and the substantial toxicity related to IFN and based
on the impressive new data, we believe that the role
of IFN will be restricted for patients with ulceration
of the primary melanoma for countries with no
access to the new drugs in this setting. For the same
reasons and owing to the superior efficacy of nivo-
lumab compared with ipilimumab, the future of the
latter as monotherapy seems scanty. Whether com-
bination of low-dose ipilimumab with nivolumab
would have a place in the adjuvant setting remains
an open question, and BMS-219 will definitely give
new insights with early results expected in the fol-
lowing 2–3 years.
In addition to enrollment into clinical trials,
which is the first-line choice for melanoma patients
with high-risk of recurrence, nivolumab would be
the appropriate adjuvant therapy for all patients
independent of mutation status or ulceration
(Fig. 1). For V600 mutant patients, combination
dabrafenib and trametinib is a considerable alterna-
tive (Fig. 1). Whenever comparing the available
evidence, the data of Combi-AD are more mature,
although consistent to Checkmate 238 (Table 1).
Decision should be based on individual factors such
as toxicity profile, convenience of oral medication,
or presence of cardiovascular risk factors and history
of autoimmune disease.
One important question arising is whether all
stage III or M1a patients should receive adjuvant
therapy. Both DECOG and MSLT 2 trials showed no
differences in clinical outcome after complete
lymphadenectomy (CLND) [63,64]. Several coun-
tries do not currently recommend CLND whenever
micrometastasis of less than 1mm in SLNB (clini-
cally occult disease) is present; instead patients
undergomore intensive surveillance.We favor adju-
vant treatment in high-risk patients from stage IIIB/
IIIC, whereas the recommendations on stage IIIA
(T1a/b-T2a N1a or N2a) depend on tumor load in
SLNB with a cut off of 2mm (Fig. 1). In general, and
according to the AJCC eighth edition, IIIA patients
have a favorable prognosis compared with IIIB and
IIIC patients with a 10-year survival of 88 versus 77
and 60%, respectively. Five-year survival for patients
with metastasis of a maximum dimension of 2–
4mm in SLNB was similar to that of 1–2mm (86
versus 89%, respectively). In IIIB–IIIC stages with
clinically occult N disease only (pT2b-4b N1a/N2a)
the approach is similar to clinically detectable dis-
ease (pN1b-N3c), where adjuvant treatment is
strongly recommended, as ulceration and tumor
thickness are both strong predictors of impaired
outcome in patients with N-positive disease.
CONCLUSION
Taking into consideration the limited maturity of
the data available, a definite suggestion of the first-
line adjuvant treatment remains onerous. Nivolu-
mab seems to fully substitute ipilimumab with a
statistically significant improvement in RFS and less
FIGURE 1. First-line choice recommendation for adjuvant treatment.
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toxicities. Combination dabrafenib and trametinib
presents an important alternative in BRAF mutant
patients (Fig. 1). Additionally, the use of both agents
in neo-adjuvant setting offers very attractive choices
for future clinical trial design.
All in all, the ongoing evaluation of antitumor
antigens, the identification of new biomarkers and
the understanding of treatment resistance mecha-
nisms is expected to guide the selection of treatment
and maximize the antitumor response.
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